Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and ...

interleukin 23 (IL-23) inhibitors might be exceptional, particularly if used early and in relatively high doses, according to two sets of research. “There are now a lot of clinicians and ...

IL-23 is a cytokine secreted by activated monocyte/macrophages and dendritic cells that is known to be a driver of immune-mediated diseases including active psoriatic arthritis. 2,3,4,5,6 ...

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage ...

I think combination therapy is coming; it’s just a question of which combinations,’ says Arthur Kavanaugh, MD.

Blocking IL-23 may block other proinflammatory cytokines implicated in psoriasis. ORLANDO — Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among ...

"The approval of TREMFYA offers an IL-23 inhibitor that has shown robust rates of endoscopic remission with both subcutaneous and intravenous induction regimens. Importantly, the fully ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s (NYSE JNJ) Tremfya (guselkumab), the ...